Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lunai BioworksSTU:2Q5 26 EPS without NRI is €-6.33 as of Mar. 2026. GuruFocus rates STU:2Q5 with a GF Score™ of 26/100. The stock has 6 warning signs investors should review. Among 1,166 Biotechnology companies, Lunai Bioworks ranks better than 83.28% on this metric.
Lunai Bioworks's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was €-0.71.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was €-6.33.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Lunai Bioworks's EPS without NRI or its related term are showing as below:
STU:2Q5'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -207.3 Med: -15.25 Max: 47.2
Current: 47.2
STU:2Q5's 3-Year EPS without NRI Growth Rate is ranked better than 83.28% of 1166
companies
in the Biotechnology industry
Industry Median: 16.2
vs STU:2Q5: 47.20
Lunai Bioworks's EPS (Diluted) for the
three
months ended in Mar. 2026 was €-0.69.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-53.21.
Lunai Bioworks's EPS (Basic) for the
three
months ended in Mar. 2026 was €-0.69.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €-53.21.
Lunai Bioworks (STU:2Q5) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Lunai Bioworks EPS without NRI Related Terms
Lunai Bioworks EPS without NRI Historical Data
* Premium members only.
The historical data trend for Lunai Bioworks's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:2Q5 vs BCLI, BIVI, XCUR: EPS without NRI Comparison
For the Biotechnology subindustry, Lunai Bioworks's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lunai Bioworks PE Ratio without NRI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lunai Bioworks's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Lunai Bioworks's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-6.33
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lunai Bioworks (STU:2Q5) has a EPS without NRI of €-6.33 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Lunai Bioworks and its competitors. According to the industry distribution chart, Lunai Bioworks ranks #195 out of 1166 companies in the Biotechnology industry, placing it in the top 16.7%.
Is Lunai Bioworks' EPS without NRI too high?
Lunai Bioworks' current EPS without NRI is €-6.33. Based on the distribution chart, Lunai Bioworks ranks #195 out of 1166 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Lunai Bioworks has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Lunai Bioworks' EPS without NRI compare to BCLI and BIVI?
According to the Biotechnology industry distribution chart, Lunai Bioworks ranks #195 out of 1166 companies for EPS without NRI. This places Lunai Bioworks in the top 17% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 16.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.20, based on 1,166 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Lunai Bioworks and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lunai Bioworks's current EPS without NRI is €-6.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lunai Bioworks stock overvalued right now?
Lunai Bioworks (STU:2Q5) has a current EPS without NRI of €-6.33. The current EPS without NRI is €-6.33. Lunai Bioworks' overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Lunai Bioworks (STU:2Q5), the current EPS without NRI is €-6.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.
26GF Score
Get the complete analysis for STU:2Q5
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2Q5 has been successfully added to your 
